{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:26:51Z","timestamp":1789590411607,"version":"build-2803163510"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s55928","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T21:57:21Z","timestamp":1447970241000},"page":"1719","source":"Crossref","is-referenced-by-count":5,"title":["Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis"],"prefix":"10.2147","author":[{"given":"Ori","family":"Elkayam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Elalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,11]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=28064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:22:38Z","timestamp":1477866158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/long-term-safety-and-efficacy-of-infliximab-for-the-treatment-of-ankyl-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s55928","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}